Changes in 11β-hydroxysteroid dehydrogenase type 2 expression in a low-protein rat model of intrauterine growth restriction

Nephrology Dialysis Transplantation

Volumn 25, Issue 10, 2010, Pages 3195-3203

  Östreicher, Iris ^a   Almeida, Jorge Reis ^a,b   Campean, Valentina ^a   Rauh, Manfred ^a   Plank, Christian ^a   Amann, Kerstin ^a   Dötsch, Jörg ^a,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

cortisol; cortisone; fetal programming; intrauterine growth restriction; small baby syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; CALBINDIN; CORTICOSTERONE; DEHYDROCORTICOSTERONE; HYDROCORTISONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; 11-DEHYDROCORTICOSTERONE; DRUG DERIVATIVE; GLUCOCORTICOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BORDERLINE HYPERTENSION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; FEMALE; GENE EXPRESSION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTRAUTERINE GROWTH RETARDATION; KIDNEY DISTAL TUBULE; MATERNAL NUTRITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RESTRICTION; RAT; REVERSE TRANSCRIPTION; TANDEM MASS SPECTROMETRY; ANIMAL; BLOOD; ENZYMOLOGY; GENETICS; PHYSIOLOGY; WISTAR RAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANIMALS; CORTICOSTERONE; DIET, PROTEIN-RESTRICTED; FEMALE; FETAL GROWTH RETARDATION; HYPERTENSION; RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER;

EID: 77957230152     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq354     Document Type: Article

References (36)

1. Gamborg M, Byberg L, Rasmussen F et al. Birth weight and systolic blood pressure in adolescence and adulthood: meta-regression analysis of sex-and age-specific results from 20 Nordic studies. Am J Epidemiol 2007; 166: 634-645
2. Nuyt AM. Mechanisms underlying developmental programming of elevated blood pressure and vascular dysfunction: evidence from human studies and experimental animal models. Clin Sci (Lond) 2008; 114: 1-17
3. Vehaskari VM, Aviles DH, Manning J. Prenatal programming of adult hypertension in the rat. Kidney Int 2001; 59: 238-245
4. Keller G, Zimmer G, Mall G et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101-108
5. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1988; 1: 335-347
6. Gross ML, Amann K, Ritz E. Nephron number and renal risk in hypertension and diabetes. J Am Soc Nephrol 2005; 16: S27-S29
7. Hoy WE, Hughson MD, Bertram JF et al. Nephron number, hypertension, renal disease, and renal failure. J Am Soc Nephrol 2005; 16: 2557-2564
8. Bertram C, Trowern AR, Copin N et al. The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11beta-hydroxysteroid dehydrogenase: potential molecular mechanisms underlying the programming of hypertension in utero. Endocrinology 2001; 142: 2841-2853
9. Fehrman-Ekholm I, Duner F, Brink B et al. No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up. Transplantation 2001; 72: 444-449
10. Narkun-Burgess DM, Nolan CR, Norman JE et al. Forty-five year follow-up after uninephrectomy. Kidney Int 1993; 43: 1110-1115
11. Bogdarina I, Welham S, King PJ et al. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res 2007; 100: 520-526
12. Plank C, Meissner U, Rauh M et al. Cortisol-cortisone ratios in small for gestational age (SGA) children without postnatal catch-up growth. Clin Endocrinol (Oxf) 2007; 67: 304-309
13. Krozowski Z, Li KX, Koyama K et al. The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol 1999; 69: 391-401
14. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170
15. Seckl JR, Walker BR. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 2004; 15: 418-424
16. Bertram CE, Hanson MA. Animal models and programming of the metabolic syndrome. Br Med Bull 2001; 60: 103-121
17. Struwe E, Berzl D, Schild R et al. Simultaneously reduced gene expression of cortisol-activating and cortisol-inactivation enzymes in placentas of small-for-gestational-age neonates. Am J Obstet Gynecol 2007; 197: 43.e1-43.e6
18. Vogeser M, Briegel J, Jacob K. Determination of serum cortisol by isotope-dilution liquid-chromatography electrospray ionization tandem mass spectrometry with on-line extraction. Clin Chem Lab Med 2001; 39: 944-947
19. Amann K, Irzyniec T, Mall G et al. The effect of enalapril on glo-merular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis. J Hypertens 1993; 11: 969-975
20. Dimmler A, Haas CS, Cho S et al. Laser capture microdissection and real-time PCR for analysis of glomerular endothelin-1 gene expression in mesangiolysis of rat anti-Thy 1.1 and murine Habu Snake Venom glomerulonephritis. Diagn Mol Pathol 2003; 12: 108-117
21. Vekaria RM, Shirley DG, Sevigny J et al. Immunolocalization of ectonucleotidases along the rat nephron. Am J Physiol Ren Physiol 2006; 290: F550-F560
22. Gluckman PD, Hanson MA, Cooper C et al. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008; 359: 61-73
23. Barker DJ, Gluckman PD, Godfrey KM et al. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993; 341: 938-941
24. Csaba G. Receptor ontogeny and hormonal imprinting. Experientia 1986; 42: 750-759
25. Seckl JR. Glucocorticoids, feto-placental 11 beta-hydroxysteroid dehydrogenase type 2, and the early life origins of adult disease. Steroids 1997; 62: 89-94
26. Seckl JR, Yau J, Holmes M. 11Beta-hydroxysteroid dehydrogenases: a novel control of glucocorticoid action in the brain. Endocr Res 2002; 28: 701-707
27. Seckl JR. Prenatal glucocorticoids and long-term programming. Eur J Endocrinol 2004; 151: U49-U62
28. Schoof E, Girstl M, Frobenius Wet al. Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprosta-glandin dehydrogenase in human placenta of patients with pre-eclampsia. J Clin Endocrinol Metab 2001; 86: 1313-1317
29. McTernan CL, Draper N, Nicholson H et al. Reduced placental 11be-ta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab 2001; 86: 4979-4983
30. Shams M, Kilby MD, Somerset DA et al. 11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum Reprod 1998; 13: 799-804
31. Holmes MC, Abrahamsen CT, French KL et al. The mother or the fetus? 11Beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids. J Neurosci 2006; 26: 3840-3844
32. Ferrari P, Krozowski Z. Role of the 11beta-hydroxysteroid dehydro-genase type 2 in blood pressure regulation. Kidney Int 2000; 57: 1374-1381
33. Condon J, Gosden C, Gardener D et al. Expression of type 2 11be-ta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. J Clin Endocrinol Metab 1998; 83: 4490-4497
34. Gong R, Morris DJ, Brem AS. Human renal 11beta-hydroxysteroid dehydrogenase 1 functions and co-localizes with COX-2. Life Sci 2008; 82: 631-637
35. Wyrwoll CS, Mark PJ, Waddell BJ. Developmental programming of renal glucocorticoid sensitivity and the renin-angiotensin system. Hypertension 2007; 50: 579-584
36. Plank C, Östreicher I, Hartner A et al. Intrauterine growth retardation aggravates the course of acute mesangioproliferative glomerulone-phritis in the rat. Kidney Int 2006; 70: 1974-1982